Ken Fisher acquired 158 Thousand Myriad Genetics shares worth $2.84 Million. That's 0.00% of their equity portfolio (541st largest holding). The first Myriad Genetics trade was made in Q4 2014. Since then Ken Fisher bought shares 21 more times and sold shares on eleven occasions. The investor's estimated purchase price is $4.41 Million, resulting in a loss of 36%.
The documented report on Global Genomic Biomarker Market by Reports Globe aims to offer an organized and methodical strategy for important aspects that have ...
Jumbo News, almost 3 years agoThis Genomic Biomarkers concerning the Genomic Biomarkers market has been published to assist the user in understanding the market as a whole, its definition...
OpenPR, over 3 years agoDUBLIN, Dec. 16, 2020 /PRNewswire/ -- The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. "Global Ge...
PR Newswire, over 3 years ago“Global Clinical Oncology Next Generation Sequencing Market- Industry Trends and Forecast to 2027” Worldwide Industry Size, Offer and trends analysis during ...
OpenPR, over 3 years ago